Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

PainReform Ltd. PRFX

Healthcare  —  Drug Manufacturers Specialty & Generic
0.98 0.00 0.00% as of 25 Sep
Market cap
$3.0M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

PainReform Ltd. (PRFX) Business Profile

Updated before January 2025

Company Overview

PainReform Ltd. (PRFX) is a clinical-stage specialty pharmaceutical company focused on the reformulation of established pain medications. Founded in 2007 and headquartered in Herzliya, Israel, the company aims to address unmet needs in the pain management market by developing innovative, extended-release drug delivery systems. PRFX is led by a team of experienced professionals in the pharmaceutical and biotechnology industries. Key leadership includes CEO Eli Hazum, Ph.D., who brings decades of experience in drug development and commercialization, and CFO Ron Mayron, who has a strong background in financial management and strategic planning.

Core Business Segments

PainReform Ltd. operates primarily in the pain management sector, with a focus on reformulating existing drugs to improve their efficacy, safety, and patient compliance. The company’s core business segments include:

Reformulated Pain Medications

  • PRF-110: The company’s flagship product, PRF-110, is a proprietary extended-release formulation of ropivacaine, a widely used local anesthetic. PRF-110 is designed to provide prolonged pain relief for up to 72 hours post-surgery, reducing the need for opioids and improving patient outcomes. The product is currently in advanced clinical trials and has shown promising results in terms of safety and efficacy.

Drug Delivery Technologies

  • Extended-Release Platforms: PainReform specializes in developing drug delivery systems that extend the duration of action of existing medications. These platforms are designed to enhance patient compliance and reduce the frequency of dosing.

Research and Development Services

  • Clinical Trials and Studies: PainReform invests heavily in R&D to ensure the safety and efficacy of its products. The company collaborates with leading research institutions and healthcare providers to conduct clinical trials and gather data to support regulatory approvals.

Business Model

PainReform’s business model revolves around the reformulation of existing drugs to create value-added products that address unmet medical needs. The company generates revenue through:

  • Licensing Agreements: PainReform partners with pharmaceutical companies to license its proprietary formulations and drug delivery technologies.
  • Collaborations: The company collaborates with healthcare providers and research institutions to develop and commercialize its products.
  • Future Product Sales: Once its products receive regulatory approval, PainReform plans to generate revenue through direct sales and distribution agreements.

Strategic Direction

PainReform is committed to becoming a leader in the pain management market by focusing on innovation, sustainability, and strategic growth. Key strategic initiatives include:

  • Advancing PRF-110: The company is prioritizing the completion of clinical trials for PRF-110 and aims to secure regulatory approvals in key markets, including the United States and Europe.
  • Expanding Product Portfolio: PainReform plans to leverage its drug delivery technologies to develop additional reformulated pain medications.
  • Sustainability Goals: The company is exploring eco-friendly manufacturing processes and aims to minimize its environmental footprint.
  • Global Market Penetration: PainReform is actively seeking partnerships and distribution agreements to expand its presence in international markets.

Competitive Landscape

PainReform operates in a highly competitive market, facing competition from both large pharmaceutical companies and smaller biotech firms. Key competitors include:

  • Pacira BioSciences, Inc.: Known for its flagship product, Exparel, an extended-release local anesthetic.
  • Heron Therapeutics: Focused on developing pain management solutions, including extended-release formulations.
  • AcelRx Pharmaceuticals: Specializes in novel pain management therapies, including sublingual formulations.

Despite the competition, PainReform differentiates itself through its proprietary drug delivery technologies and focus on reformulating established medications.

Risk Factors

PainReform faces several risks that could impact its operations and financial performance:

  • Regulatory Risks: The company’s products are subject to stringent regulatory approvals, which can be time-consuming and costly.
  • Market Dependence: PainReform’s success is heavily reliant on the commercial success of PRF-110.
  • Supply Chain Disruptions: The company depends on third-party manufacturers and suppliers, making it vulnerable to supply chain disruptions.
  • Competition: Intense competition in the pain management market could impact PainReform’s market share and profitability.

Recent Developments

PainReform has made significant progress in recent years, including:

  • Clinical Trials for PRF-110: The company has successfully completed Phase II clinical trials for PRF-110 and is currently conducting Phase III trials.
  • Partnerships and Collaborations: PainReform has entered into strategic partnerships with leading research institutions to advance its R&D efforts.
  • Regulatory Filings: The company has submitted regulatory filings for PRF-110 in multiple jurisdictions and is awaiting approvals.

Investment Considerations

Investors considering PainReform should weigh the following strengths and risks:

Strengths

  • Innovative Product Pipeline: PainReform’s focus on reformulating existing drugs provides a unique value proposition.
  • Experienced Leadership: The company is led by a team of seasoned professionals with extensive industry experience.
  • Growing Market: The global pain management market is expected to grow significantly, providing ample opportunities for PainReform.

Risks

  • Regulatory Uncertainty: Delays in regulatory approvals could impact the company’s timeline for product commercialization.
  • Financial Risks: As a clinical-stage company, PainReform is not yet profitable and relies on external funding.
  • Market Competition: Intense competition could limit the company’s market penetration and revenue growth.

Conclusion

PainReform Ltd. is well-positioned to become a leader in the pain management market, thanks to its innovative drug delivery technologies and focus on reformulating established medications. While the company faces several risks, its strong leadership, promising product pipeline, and strategic growth initiatives provide a solid foundation for future success. As the global demand for effective pain management solutions continues to grow, PainReform is poised to capitalize on this trend and deliver value to patients and investors alike.